Mounting evidence suggests safety and efficacy of psychedelic compounds as potential
novel therapeutics in psychiatry. Ketamine has been approved by the Food and Drug …

BackgroundTreatment-resistant schizophrenia (TRS) is associated with high levels of
functional impairment, healthcare usage and societal costs. Cross-sectional studies may …

Clinical practice guidelines (CPGs) translate evidence into recommendations to improve
patient care and outcomes. To provide an overview of schizophrenia CPGs, we conducted a …

Objectives: This guideline provides recommendations for the clinical management of
schizophrenia and related disorders for health professionals working in Australia and New …

The American Psychiatric Association Practice Guideline for the Treatment of Patients With
Schizophrenia seeks to reduce these substantial psychosocial and public health …

Abstract Treatment-resistant schizophrenia (TRS) will affect about one in three patients with
schizophrenia. Clozapine is the only treatment approved for TRS, and patients should be …

Since the discovery of chlorpromazine (CPZ) in 1952, first-generation antipsychotics (FGAs)
have revolutionized psychiatric care in terms of facilitating discharge from hospital and …

Individuals living with serious mental illness are often difficult to engage in ongoing
treatment, with high dropout rates. Poor engagement may lead to worse clinical outcomes …

We conducted a systematic review of meta-analyses and systematic reviews to evaluate the
impact of cannabis use on the onset and course of psychoses. Following a systematic …

People with severe mental illness have a considerably shorter lifespan than the general
population. This excess mortality is mainly due to physical illness. Next to mental illness …